Table 1 Clinicopathologic characteristics of patients in two cohorts

Training cohort

  (TCGA-LAML, N = 145)

72

73

 Age

<60y

50 (69.44)

35 (47.95)

0.013

≥60y

22 (30.56)

38 (52.05)

 Gender

female

36 (50)

31 (42.47)

0.457

male

36 (50)

42 (57.53)

 Clinical characteristics (mean ± sd)

Blast count (%)

45.39 ± 34.93

31.14 ± 27.6

0.006

Leukocyte (x10^9)

33.99 ± 47.66

36.75 ± 39.14

0.703

Hemoglobin (g/L)

9.62 ± 1.53

9.53 ± 1.41

0.692

Platelet count (x10^9)

57.21 ± 50.8

69.73 ± 48.84

0.130

 Cytogenetic risk

Poor

14 (20)

12 (16.44)

< 1e-04

Intermediate

31 (44.29)

57 (78.08)

Favorable

25 (35.71)

4 (5.48)

 Mutations

FLT3

20 (28.17)

21 (29.17)

1.000

NPM1

16 (22.54)

26 (36.11)

0.109

DNMT3A

16 (22.54)

20 (27.78)

0.596

IDH1

11 (15.49)

4 (5.56)

0.095

IDH2

7 (9.86)

8 (11.11)

1.000

NRAS

4 (5.63)

6 (8.33)

0.760

CEBPA

9 (12.68)

3 (4.17)

0.125

RUNX1

5 (7.04)

9 (12.5)

0.414

TET2

9 (12.68)

6 (8.33)

0.565

ASXL1

1 (1.41)

2 (2.78)

1.000

TP53

3 (4.23)

7 (9.72)

0.336

Validation cohort

  (Beat-AML, N = 139)

69

70

 Age

<60y

36 (52.17)

35 (50)

0.931

≥60y

33 (47.83)

35 (50)

 Gender

female

36 (52.17)

27 (38.57)

0.149

male

33 (47.83)

43 (61.43)

 Cytogenetic risk

Poor

15 (32.61)

15 (35.71)

0.413

Intermediate

22 (47.83)

23 (54.76)

Favorable

9 (19.57)

4 (9.52)

 Mutation

FLT3

19 (27.54)

14 (20.29)

0.424

NPM1

19 (27.94)

12 (17.39)

0.203

CEBPA

1 (1.45)

0

0.994

 Fusions

CBFB-MYH11; inv (16)

2 (2.9)

2 (2.86)

1.000

MLLT3-KMT2A; t (9;11)

0

5 (7.14)

0.071

RUNX1-RUNX1T1; t (8;21)

0

2 (2.86)

0.482